-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
In connection with recent stock splits, psychedelics biotech Clearmind Medicine Inc. (OTC:CMNDF) announced it will proceed with the consolidation of all its issued and outstanding common shares on a 1:30 basis, effective as of September 30, 2022.
Clearmind's 39,592,344 common shares to date issued and outstanding will be reduced to approx. 1,319,744 on a post-consolidation basis, with no fractional shares to be issued.
After the consolidation, trading of the common shares at the CSE will begin on or about October 3, 2022 under the same company name and trading symbol. Outstanding stock options and share purchase warrants will also become adjusted by the new ratio, as will their respective exercise prices.
Recap on Clearmind: IP currently includes seven patent families, yet the company intends to seek additional patents for its proprietary compounds -such as the most recent one filed jointly with Scisparc for the treatment of metabolic syndromes- as well as to consider purchasing others' intellectual property to build its portfolio.
Mydecine Proceeds With Its New Share Subscription Agreement
In other news, Mydecine Innovations Group Inc. (OTC:MYCOF) closed the second tranche of its first issuance under a common share subscription agreement with a third-party investor signed on August 26, 2022, of which a related shelf prospectus supplement was subsequently filed on September 7, 2022.
Through the offering, the company issued 877,193 of its common shares at a price of $0.57 each for aggregate gross proceeds of $500,000, with their distribution qualified by the prospectus supplement.
Mydecine's CEO, Josh Bartch said "in biotech, the ability to access capital in all forms is very important."
Mydecine, which focuses on mental health disorders such as addictions and PTSD involves combining advanced technology with an R&D infrastructure. The company recently filed a full-patent application to the World Intellectual Property Organization for its family of short-acting MDMA-based psychedelic compounds.
Photo courtesy of Geralt on Pixabay and Wikimedia Commons.
In connection with recent stock splits, psychedelics biotech Clearmind Medicine Inc. (OTC:CMNDF) announced it will proceed with the consolidation of all its issued and outstanding common shares on a 1:30 basis, effective as of September 30, 2022.
与最近的股票拆分有关,迷幻生物科技ClearMind医药公司(场外交易代码:CMNDF)宣布将继续合并其所有已发行和已发行的普通股1:30基数,自2022年9月30日起生效。
Clearmind's 39,592,344 common shares to date issued and outstanding will be reduced to approx. 1,319,744 on a post-consolidation basis, with no fractional shares to be issued.
ClearMind的迄今已发行和已发行的39,592,344股普通股将减少到大约。按合并后基准计算为1,319,744股,不发行零碎股份。
After the consolidation, trading of the common shares at the CSE will begin on or about October 3, 2022 under the same company name and trading symbol. Outstanding stock options and share purchase warrants will also become adjusted by the new ratio, as will their respective exercise prices.
合并后,普通股将于2022年10月3日左右在CSE开始交易,公司名称和交易代码相同。已发行的股票期权和认购权证也将根据新的比率进行调整,其各自的行使价格也将随之调整。
Recap on Clearmind: IP currently includes seven patent families, yet the company intends to seek additional patents for its proprietary compounds -such as the most recent one filed jointly with Scisparc for the treatment of metabolic syndromes- as well as to consider purchasing others' intellectual property to build its portfolio.
ClearMind重述:IP目前包括七个专利系列,但该公司打算为其专有化合物申请更多专利--例如最近与Scisparc联合提交的用于治疗代谢综合征的专利--并考虑购买其他公司的知识产权以建立其产品组合。
Mydecine Proceeds With Its New Share Subscription Agreement
Mydecine继续签署新的股票认购协议
In other news, Mydecine Innovations Group Inc. (OTC:MYCOF) closed the second tranche of its first issuance under a common share subscription agreement with a third-party investor signed on August 26, 2022, of which a related shelf prospectus supplement was subsequently filed on September 7, 2022.
在其他新闻方面,Mydecine创新集团公司(场外交易代码:MYCOF)根据一项普通股认购协议,完成其首次发行的第二批股票第三方投资者于2022年8月26日签署,其中相关的搁置招股说明书附录随后于2022年9月7日提交。
Through the offering, the company issued 877,193 of its common shares at a price of $0.57 each for aggregate gross proceeds of $500,000, with their distribution qualified by the prospectus supplement.
通过供品,该公司以每股0.57美元的价格发行了877,193股普通股总收益为500,000美元,其分配符合招股说明书补编的要求。
Mydecine's CEO, Josh Bartch said "in biotech, the ability to access capital in all forms is very important."
Mydecine的首席执行官乔希·巴奇他说:“在生物技术领域,获得各种形式的资本的能力非常重要。”
Mydecine, which focuses on mental health disorders such as addictions and PTSD involves combining advanced technology with an R&D infrastructure. The company recently filed a full-patent application to the World Intellectual Property Organization for its family of short-acting MDMA-based psychedelic compounds.
Mydecine,它专注于成瘾和创伤后应激障碍等精神健康障碍,涉及将先进技术与研发基础设施相结合。该公司最近向世界知识产权组织提交了其基于MDMA的短效迷幻化合物系列的完整专利申请。
Photo courtesy of Geralt on Pixabay and Wikimedia Commons.
照片由Geralt在Pixabay和Wikimedia Commons上提供。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧